Australian Competition and Consumer Commission v Baxter Healthcare Pty Limited & Ors

The Australian Competition and Consumer Commission (ACCC) brought proceedings against Baxter Healthcare Pty Limited and Baxter Service Company Pty Limited (Baxter) in the Federal Court of Australia. The dispute concerned allegations that Baxter had engaged in anti-competitive conduct by misusing its dominant position in the market for the supply of certain intravenous (IV) fluid products and related services. The ACCC contended that Baxter had leveraged its market power to prevent or hinder competitors from supplying these products and services to public hospitals.

The central legal issues before the Full Federal Court were whether Baxter had engaged in conduct that contravened section 46 of the *Trade Practices Act 1974* (Cth) (now the *Competition and Consumer Act 2010* (Cth)). Specifically, the court had to determine if Baxter had taken advantage of its substantial degree of market power in the relevant markets for IV fluids and related services, and if so, whether its conduct had the purpose, effect, or likely effect of substantially lessening competition. The court also considered the definition of the relevant markets and Baxter's alleged misuse of its position within those markets.

The Full Federal Court's reasoning focused on the application of section 46 to Baxter's conduct. The court analysed the evidence presented to establish Baxter's market power and whether it had taken advantage of that power. It considered the nature of Baxter's contracts with public hospitals and the terms under which it supplied its products and services. The court applied established principles of competition law, including the tests for market definition and the assessment of substantial lessening of competition, to determine whether Baxter's actions were anti-competitive. The court ultimately found that Baxter had not contravened section 46 of the Act.